To view the fulltext, please log in
To view the pdf, please log in
The range of clinical applications for stereotactic body radiation therapy (SBRT) continues to expand based on clinical outcomes data from prospective trials and carefully analyzed institutional experiences. As a result of this strong scientific foundation, there has been burgeoning implementation of SBRT and other forms of hypofractionated radiation therapy in the practice of radiation oncology worldwide. In spite of the clinical successes achieved thus far – or, perhaps, because of them – fundamental questions about SBRT remain and have come into greater focus. Where and when is SBRT optimally integrated into the range of evolving modern multidisciplinary cancer treatment programs? What scientific insights (biological, technical and medical) might lead to further improvements in the efficacy of SBRT? What efficiencies are needed to achieve greater availability of SBRT? These and many other questions, fueled by the clinical accomplishments of SBRT to date, provide compelling directions for further exploration in scientific and clinical studies and further contributes to discoveries already transforming the practice of radiation oncology.
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Whelan TJ Pignol JP Levine MN: Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513-520
- Eriksson D Stigbrand T: Radiation-induced cell death mechanisms. Tumour Biol 2010; 31: 363-372
- Ewing J: Factors determining radioresistance in tumors. Radiology 1930; 14: 186-190
- Garcia-Barros M Paris F Cordon-Cardo C: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-1159
- Yamada Y Bilsky MH Lovelock DM: High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys 2008; 71: 484-490
- Li F Huang Q Chen J: Apoptotic cells activate the ‘phoenix rising’ pathway to promote wound healing and tissue regeneration. Sci Signal 2010; 3: ((110)) ra13
- Lea DE Catcheside DG: The mechanism of the induction by radiation of chromosome aberrations in Tradescantia. J Genetics 1942; 44: 216-245
- Guerrero M Li XA: Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. Phys Med Biol 2004; 49: 4825-4835
- Curtis SB: Lethal and potentially lethal lesions induced by radiation - a unified repair model. Radiat Res 1986; 106: 252-270
- Park C Papiez L Zhang S: Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 2008; 70: 847-852
- Astrahan M: Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation. Med Phys 2008; 35: 4161-4172
- Smith BD Arthur DW Buchholz TA: Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009; 74: 987-1001
- Timmerman R Paulus R Galvin J: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-1076
- Hellman S Weichselbaum RR: Oligometastases. J Clin Oncol 1995; 13: 8-10
- Milano MT Zhang H Metcalfe SK: Oligo-metastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat 2009; 115: 601-608
- Miles DW Chan A Dirix LY: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-3247
- Rusthoven KE Hammerman SF Kavanagh BD: Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol 2009; 48: 578-583
- Madsen BL Hsi RA Pham HT: Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007; 67: 1099-1105
- Katz AJ Santoro M Ashley R: Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 2010; 10: 1
- King CR Brooks JD Gill H: Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009; 73: 1043-1048
- Mahadevan A Jain S Goldstein M: Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010; 78: 735-742
- Tse RV Hawkins M Lockwood G: Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2008; 26: 657-664
- Rusthoven KE Kavanagh BD Cardenes H: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009; 27: 1572-1578
- Rusthoven KE Kavanagh BD Burri SH: Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009; 27: 1579-1584